Gerresheimer successfully completes acquisition of Blitz LuxCo

Gerresheimer has succesfully completed the acquisition of Blitz LuxCo, the holding company of the Bormioli Pharma Group announced in May 2024. With this acquisition, Gerresheimer strengthens its European footprint with additional production sites and underpins its market position as a leading full-service provider and global partner for the pharma and biotech industries.  

“Following the successful completion of the acquisition, we can now focus on the integration of Bormioli Pharma into the Gerresheimer Group, » explains Dietmar Siemssen, CEO of Gerresheimer AG. « We are convinced that our customers will benefit from the expansion of the product portfolio and new, integrated systems and solutions. »

In 2023, Bormioli Pharma generated sales of around EUR 371 million and an Adj. EBITDA margin of around 22%. The company manufactures pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems. In the plastics segment, Bormioli Pharma is one of the leading suppliers of pharmaceutical plastic systems and solutions. In the glass segment, Bormioli Pharma has an attractive portfolio for parenteral and other pharmaceutical primary packaging.

The acquisition creates a new, strong Moulded Glass unit with a diversified product portfolio for the pharmaceutical, cosmetics, food and beverage industries. This globally active unit offers new options for a strategic reset for the best growth prospects and competitiveness, which will be evaluated in the coming months.

Bormioli Pharma will become part of the Gerresheimer Group and will be fully consolidated retroactively as of December 1, 2024, the start of Gerresheimer’s new financial year 2025. Therefore, on February 26, 2025, together with the results for the financial year 2024, Gerresheimer will publish a new guidance for 2025 and a new mid-term guidance for the combined company.